NCT03786783 - Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

September 19, 2026

Conditions

GanglioneuroblastomaHigh Risk Neuroblastoma

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo ASCT

DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Dexrazoxane

Given IV

BIOLOGICAL

Dinutuximab

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Etoposide

Given IV

RADIATION

External Beam Radiation Therapy

Undergo EBRT

DRUG

Isotretinoin

Given PO

DRUG

Melphalan

Given IV

BIOLOGICAL

Sargramostim

Given SC

DRUG

Thiotepa

Given IV

DRUG

Topotecan

Given IV

DRUG

Vincristine

Given IV

Trial Locations (10)

1145

Starship Children's Hospital, Grafton

2145

The Children's Hospital at Westmead, Westmead

3052

Royal Children's Hospital, Parkville

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

38105

Saint Jude Children's Research Hospital, Memphis

84113

Primary Children's Hospital, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH